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Abstract
Background and Objectives Long-term use of antiretro-
viral therapy (ART) to treat HIV infection has been asso-
ciated with dyslipidemia and metabolic and cardiovascular
complications. Available options for patients at risk of
cardiovascular disease include antiretroviral drugs with
improved lipid profiles. Dolutegravir is one of a new
generation of HIV integrase inhibitors recently incorpo-
rated into the US Department of Health and Human Ser-
vices, German, Spanish, and Italian HIV treatment
guidelines as a preferred first-line third agent in combina-
tion with dual nucleoside reverse transcriptase inhibitor
(NRTI) backbone therapies. To understand the lipid profile
of dolutegravir in the context of combination ART, we
analyzed the lipid outcomes at 48 weeks in ART-naive
participants in four phase IIb–IIIb clinical trials.
Methods Variables included in this analysis were total
cholesterol (TC), low-density lipoprotein (LDL) choles-
terol (LDL-C), high-density lipoprotein (HDL) cholesterol
(HDL-C), TC/HDL ratio, and triglycerides at baseline and
week 48.
Results In a comparative analysis, dolutegravir demon-
strated a broadly neutral effect on lipids versus efavirenz or
ritonavir-boosted darunavir; in both comparisons, patients
taking dolutegravir exhibited smaller increases in TC,
LDL-C, and triglyceride levels. In comparison with ralte-
gravir, dolutegravir exhibited a similar lipid profile,
including small increases in TC, LDL-C, and triglyceride
levels for both agents. In the pooled dolutegravir analysis,
minimal increases in LDL-C and triglycerides were
observed but mean values at 48 weeks remained below
National Cholesterol Education Program target levels.
HDL-C levels increased at 48 weeks, and the mean TC/
HDL-C ratio was 0.6 at 48 weeks; these values are asso-
ciated with a lower risk of cardiovascular disease.
Conclusions Together, these data show that dolutegravir
has a safer lipid profile in combination ART and provides
an important treatment option for older patients who may
have other risk factors for metabolic syndrome or cardio-
vascular disease.
Key Points
The efficacy of dolutegravir has been demonstrated
in randomized studies in integrase inhibitor-naive
adult populations.
To date, a detailed review of the dolutegravir lipid
profile has not been provided in the literature.
Dolutegravir has shown a broadly neutral effect on
serum lipids in comparative clinical trials.
1 Introduction
Long-term use of antiretroviral therapy (ART) is related to
metabolic (dyslipidemia, insulin resistance, and diabetes)
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and cardiovascular complications [1, 2]. ART can induce
raised levels of total cholesterol (TC), low-density lipo-
protein cholesterol (LDL-C), and triglycerides (TG), as
well as variable effects on high-density lipoprotein cho-
lesterol (HDL-C) levels [3]. In a large cross-sectional
study, the prevalence of hypercholesterolemia ([240 mg/
dL), hypertriglyceridemia ([200 mg/dL), and low HDL-C
(\35 mg/dL) was 10–27, 23–40, and 19–27 %, respec-
tively, depending on the antiretroviral regimen [4].
The treatment options available for the management of
dyslipidemia in HIV infection are similar to those in the
general population, with an additional option of starting
therapy or switching to a different antiretroviral class with
a neutral lipid profile [2]. Given the increasing number of
people living with HIV infection for longer periods of time,
the lipid profile of new antiretroviral agents is a critical
selection factor when choosing among different options for
a treatment regimen.
Dolutegravir is an unboosted integrase strand transfer
inhibitor (INSTI) recently approved for combination ther-
apy with other antiretroviral agents in HIV-1-infected
subjects. Two phase III trials of dolutegravir 50 mg once
daily, in combination with fixed-dose dual nucleoside
reverse transcriptase inhibitors (NRTIs), have demon-
strated non-inferiority to raltegravir-based regimens [5–7];
one phase III study showed superiority to efavirenz/ten-
ofovir disoproxil fumarate (tenofovir)/emtricitabine in
ART-naive subjects [8]. Additionally, a phase IIIb study
demonstrated superiority of dolutegravir to ritonavir-
boosted darunavir when both were used in combination
with fixed-dose dual NRTI combinations [9]. As a result,
the US Department of Health and Human Services
(DHHS), German, Spanish, and Italian HIV treatment
guidelines have been updated to include dolutegravir as a
preferred first-line third agent in combination with pre-
ferred fixed-dose, dual-combination (FDC) backbones,
abacavir/lamivudine, or tenofovir disoproxil fumarate/em-
tricitabine [10].
To highlight the lipid profile of dolutegravir 50 mg once
daily in the context of combined ART, we undertook the
present analysis to describe lipid outcomes at 48 weeks in
ART-naive subjects enrolled in the four phase IIb–IIIb
clinical trials [6, 8, 9, 11].
2 Methods
Detailed methodologies for SPRING-1 (ClinicalTrials.gov
identifier: NCT00951015), SPRING-2 (ClinicalTrials.gov
identifier: NCT01227824), SINGLE (ClinicalTrials.gov
identifier: NCT01263015), and FLAMINGO (ClinicalTri-
als.gov identifier: NCT01449929) have been reported pre-
viously [5–9, 11]. In brief, SPRING-1, a phase II dose-
ranging study, randomized (1:1:1:1) 205 treatment-naive
adults to receive 10, 25, or 50 mg dolutegravir or 600 mg
efavirenz, respectively, in combination with either ten-
ofovir/emtricitabine or abacavir/lamivudine. SPRING-2
randomized 822 HIV-infected, ART-naive adults to treat-
ment with raltegravir 400 mg twice daily or dolutegravir
50 mg once daily, each with either abacavir/lamivudine
600/300 mg once daily or tenofovir/emtricitabine
600/300 mg once daily as selected by the investigator.
SINGLE randomized 833 adults to treatment with dolute-
gravir ? abacavir/lamivudine or efavirenz/tenofovir/
emtricitabine. FLAMINGO randomized 484 adults to
treatment with dolutegravir or ritonavir-boosted darunavir,
each with either abacavir/lamivudine or tenofovir/emtri-
citabine as selected by the investigator. Furthermore, pre-
specified statistical lipid analyses for SINGLE were con-
ducted (change from baseline LDL-C and TC). These
exploratory analyses were analyses of covariance that
adjusted for baseline LDL-C or TC, viral load, and CD4?.
Pre-specified analyses were also conducted for FLA-
MINGO (change from baseline LDL-C, incidence C grade
2 LDL-C). The change from baseline LDL-C was analyzed
using a repeated measures analysis of covariance, including
baseline plasma HIV-1 RNA, background dual NRTI
therapy, baseline LDL-C, treatment group, and visit. The
incidence of C grade 2 LDL-C was analyzed using a Chi-
squared test.
Data are summarized for the randomized phases of the
studies, and for all individuals who received at least one
dose of investigational product. Individuals were analyzed
according to the treatment they actually received for the
majority of time on the study, regardless of randomized
treatment group. In each study, fasting plasma samples for
lipid measurements were collected at baseline and at weeks
2, 4, 12, 16, 32, and 48. Variables included in this analysis
are TC, LDL-C, HDL-C, TC/HDL ratio, and TG at base-
line and week 48. Pooled data of fasting lipid levels from
patients assigned to receive dolutegravir in the aforemen-
tioned studies are presented as the mean concentration (mg/
dL) at baseline and week 48. We further explored differ-
ences in changes from baseline (mg/dL) to week 48 within
each study for dolutegravir and its respective comparators.
Clinically significant mean increases from baseline in
serum lipids refer to those that would suggest lipid-low-
ering interventions according to current guidelines [12].
The proportion of patients with Division of AIDS (DAIDS)
grade 2–4 elevations in TC, LDL-C, and TG is presented
by treatment group. The 2004 DAIDS severe adverse
events grading table was used for SPRING-1, while the
2009 version was used for SPRING-2, SINGLE, and
FLAMINGO. For individuals who initiated serum lipid-
lowering agents post-baseline, the last-available fasted, on-
treatment lipid values prior to lipid treatment initiation
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were used in place of future, observed on-treatment values.
Imputation continued even if the subject discontinued the
lipid-lowering agent. On-treatment missing data were not
imputed and thus a change from baseline was calculated
only for those with baseline and on-treatment values.
Individuals receiving lipid-lowering agents at baseline
were excluded from the lipid analysis.
3 Results
A total of 1,118 subjects were randomized to dolutegravir
50 mg once daily within the four ART-naive studies of the
dolutegravir development program. Table 1 describes the
baseline demographic characteristics of patients, and
specifies the number and percentage of patients co-infected
with hepatitis B and hepatitis C, as well as the percentage
of patients who received the backbone co-formulation of
abacavir/lamivudine. The median age of patients was
between 34 and 40 years. Between 32 and 40 % of patients
received abacavir/lamivudine, except in SINGLE, where
100 % of patients who received dolutegravir had abacavir/
lamivudine as the combined backbone.
Table 2 shows pooled lipid data for subjects randomized
to dolutegravir 50 mg in four studies: SPRING-1,
SPRING-2, SINGLE, and FLAMINGO, including mean
serum concentrations of TC, HDL-C, LDL-C, and TG at
baseline. Additionally shown are the mean changes in those
parameters from baseline to week 48. The proportion of
patients experiencing grade 2–4 elevations in each variable
from baseline are provided.
Figure 1 shows box plots with baseline and week 48
plasma concentrations of TC, LDL-C, HDL-C, and TG for
those individuals receiving dolutegravir. The week-48
values overlapped with baseline values.
Figure 2 shows the changes from baseline TC at week
48 across the studies, and includes the comparator study-
arm values. The changes from baseline TC were compa-
rable between dolutegravir and the comparator treatment
groups, with the exception of the SPRING-1 study, in
which participants receiving dolutegravir had smaller
changes in serum lipids than those receiving efavirenz.
Table 3 shows baseline and changes in mean lipid serum
concentrations at 48 weeks and grade 2–4 elevations in
lipids in the SPRING-2 study.
Minor increases in mean TC occurred in both the
dolutegravir and raltegravir arms. The mean LDL-C levels
showed no clinically significant increases from baseline,
with mean values at week 48 within a normal range for
both the dolutegravir and raltegravir groups. Similar small
increases were seen in mean HDL-C plasma levels in both
the dolutegravir and raltegravir arms. The mean TC:HDL
ratio slightly declined in both arms. Mean TG levels rose
from baseline in both the dolutegravir and raltegravir
groups, with elevations being slightly lower in the dolu-
tegravir group, although this difference was not clinically
significant. The proportion of patients with grade 2–4
elevations was between 5 and 8 % for TC and LDL-C, and
2 % for TG in all evaluable subjects.
In the SINGLE study (Table 4), baseline TC levels were
comparable between subjects receiving dolutegravir or ef-
avirenz. At week 48, those receiving efavirenz showed
numerically higher mean TC increases compared with
dolutegravir recipients. A pre-specified exploratory ana-
lysis of change from baseline showed the difference in
increase to be statistically significant (p = 0.005).
Numerical differences were also observed in LDL-C, with
the highest changes from baseline in patients assigned to
the efavirenz arm; the pre-specified exploratory analysis of
change from baseline showed this difference to be statis-
tically significant (p = 0.032). The mean HDL-C plasma
levels modestly increased from baseline to week 48 in both
the dolutegravir and efavirenz arms. With respect to the
TC:HDL ratio, a slight decrease from mean baseline ratio
Table 1 Baseline demographic characteristics of patients included in the studies

















Median age, years 37 40 37 35 36 35 34 34
Male 45 (88) 44 (88) 348 (85) 355 (86) 347 (84) 356 (85) 211 (87) 201 (83)
White 38 (75) 43 (86) 346 (84) 352 (86) 284 (69) 284 (68) 173 (71) 176 (73)
ABC/3TC NRTI
background
17 (33) 16 (32) 169 (41) 164 (40) 414 (100) 0 79 (33) 80 (33)
Hepatitis B and/or C 4 (8) 6 (12) 49 (12) 43 (10) 28 (7) 30 (7) 26 (11) 20 (8)
All data are expressed as n (%) unless otherwise specified
ABC/3TC abacavir/lamivudine, ATR atripla, DRV darunavir, DTG dolutegravir, EFV efavirenz, NRTI nucleoside reverse transcriptase inhibitor,
RAL raltegravir
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in both the dolutegravir and efavirenz groups was
observed, with no differences at week 48 between treat-
ment arms (-0.1). Levels of TG increased in both arms,
with no significant difference in the mean change between
the dolutegravir and efavirenz groups (17.7 vs. 18.6 mg/dL
at week 48, respectively). The proportion of patients with
grade 2–4 elevations was between 6 and 8 % for TC and
LDL-C, and 2 % for TG.
Table 2 Pooled dolutegravir mean changes from baseline of lipid serum levels from SPRING-1, SPRING-2, SINGLE, and FLAMINGO, and
maximal post-baseline emergent grade 2–4 elevations
Parameter Baseline Change from baseline to week 48 Maximum post-baseline
emergent grade 2–4 elevationsa
n Mean (SD) n Mean (SD) n/N (%)
TC (mg/dL) 953 160.5 (34) 834 9.9 (27) 78/1,118 (7)
LDL-C (mg/dL) 946 94.1 (29) 821 4.8 (21) 65/1,118 (6)
Triglycerides (mg/dL) 954 114.7 (71) 836 8.7 (85) 18/1,118 (2)
HDL-C (mg/dL) 953 43.9 (13) 834 3.6 (10) NA
TC:HDL ratio 1,013 3.9 (1) 888 -0.1 (1) NA
DAIDS Division of AIDS, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NA not applicable, SD
standard deviation, TC total cholesterol









































































































Fig. 1 Pooled DTG at baseline and at week 48 a total cholesterol,
b LDL cholesterol, c HDL cholesterol, and d triglyceride levels.
Boxes represent the first to third quartile; lines and symbols within the
box represent medians and means, respectively. Whiskers extend to
the most extreme observations within 1.5 times the length of the
interquartile range from the first and third quartiles. Points beyond the
whiskers are considered outliers. DTG dolutegravir, HDL high-
density lipoprotein, LDL low-density lipoprotein
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Figure 3 shows box plots with mean changes from
baseline to week 48 in lipid parameters across the four
comparative studies of dolutegravir versus raltegravir
(SPRING-1, SPRING-2), efavirenz (SINGLE), and riton-
avir-boosted darunavir (FLAMINGO), respectively.
Table 5 shows lipid changes in the FLAMINGO study.
The mean increase in TC in the ritonavir-boosted dar-
unavir arm from baseline to 48 weeks was clinically
significantly greater in the ritonavir-boosted darunavir
arm; a greater mean increase in LDL-C was also observed
in the ritonavir-boosted darunavir arm. In the FLA-
MINGO study, a pre-specified analysis of the mean
change from baseline to week 48 in LDL-C demonstrated
a significantly lower (p \ 0.001) LDL-C increase in the
dolutegravir group than in the ritonavir-boosted darunavir
group. The mean increase in HDL-C levels from baseline
to week 48 was small and comparable between
dolutegravir and ritonavir-boosted darunavir. With regard
to TC:HDL ratios, the dolutegravir arm showed no
increase in the TC:HDL ratio versus an increase of 0.4 in
the ritonavir-boosted darunavir arm from baseline to week
48. The mean changes in TG levels increased in the ri-
tonavir-boosted darunavir group and decreased in the
dolutegravir group.
Grade 2–4 maximum post-baseline toxicities for dolu-
tegravir and ritonavir-boosted darunavir for TC and TG
were reported in 4 versus 16 % and \1 % versus 3 % of
subjects, respectively. A similar difference was shown for
these reports with LDL-C (4 % for subjects receiving
dolutegravir vs. 14 % for those receiving ritonavir-boosted
darunavir). A pre-specified analysis showed the dolute-
gravir group had significantly fewer LDL values of grade 2
or higher than the ritonavir-boosted darunavir group






















































Fig. 2 Changes from baseline total cholesterol at week 48. Boxes
represent the first to third quartile; lines and symbols within the box
represent medians and means, respectively. Whiskers extend to the
most extreme observations within 1.5 times the length of the
interquartile range from the first and third quartiles. Points beyond
the whiskers are considered outliers. DRV/r darunavir/ritonavir, DTG
dolutegravir, EFV efavirenz, EFV/TDF/FTC efavirenz/tenofovir
disoproxil fumarate/emtricitabine, RAL raltegravir
Table 3 Mean lipid changes from baseline to week 48 in the SPRING-2 study
Parameter Treatment Baseline Change from baseline Maximum post-baseline
emergent grade 2–4 elevationsa
n Mean (SD) n Mean (SD) n/N (%)
TC (mg/dL) DTG 356 163.8 (34) 318 6.9 (28) 32/411 (8)
RAL 366 160.3 (38) 308 9.0 (29) 24/411 (6)
LDL-C (mg/dL) DTG 354 96.8 (30) 313 2.9 (21) 29/411 (5)
RAL 363 93.4 (32) 302 3.3 (23) 22/411 (5)
HDL-C (mg/dL) DTG 356 44.4 (12) 318 2.7 (11) NA
RAL 366 44.3 (13) 308 2.7 (10) NA
TC:HDL ratio DTG 356 3.9 (1) 318 -0.04 (1) NA
RAL 366 3.8 (1) 308 -0.1 (2) NA
Triglycerides (mg/dL) DTG 357 113.8 (64) 319 8.6 (91) 7/411 (2)
RAL 366 115.9 (82) 308 10.1 (93) 8/411 (2)
DAIDS Division of AIDS, DTG dolutegravir, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NA not
applicable, RAL raltegravir, SD standard deviation, TC total cholesterol
a DAIDS grading system
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4 Discussion
This analysis provides information on lipid outcomes at
48 weeks from phase IIb and III controlled studies within
the dolutegravir development programme, and allows for a
comparison of the effect on lipids of dolutegravir versus
other classes of treatments for HIV, including non-NRTIs
(NNRTIs; efavirenz), boosted protease inhibitors
(ritonavir-boosted darunavir), and a first-generation INSTI,
raltegravir. Our data confirm initial observations suggest-
ing a minimal effect of dolutegravir in combination with
NRTIs on serum lipids in ART-naive subjects infected with
HIV [11]. Dolutegravir also demonstrated an effect on
serum lipids that was smaller than that observed with ef-
avirenz or boosted darunavir, regardless of the choice of
NRTI backbone.
Table 4 Mean lipid changes from baseline to week 48 in the SINGLE study
Parameter Treatment Baseline Change from baseline Maximum post-baseline
emergent grade 2–4 elevationsa
n Mean (SD) n Mean (SD) n/N (%)
TC (mg/dL) DTG 346 158.9 (34) 296 17.1 (26) 35/414 (8)
EFV 355 158.2 (37) 279 24.1 (34) 32/419 (8)
LDL-C (mg/dL) DTG 342 93.1 (29) 289 8.5 (21) 32/414 (8)
EFV 353 92.7 (22) 273 13.1 (30) 24/419 (6)
HDL-C (mg/dL) DTG 346 43.4 (13) 296 5.2 (9) NA
EFV 355 43.6 (13) 279 8.0 (11) NA
TC:HDL ratio DTG 374 3.9 (1) 320 -0.1 (1) NA
EFV 381 3.9 (1) 302 -0.1 (1) NA
Triglycerides (mg/dL) DTG 346 115.0 (78) 296 17.7 (94) 8/414 (2)
EFV 355 111.2 (67) 279 18.6 (92) 9/419 (2)
DAIDS Division of AIDS, DTG dolutegravir, EFV efavirenz, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein
cholesterol, NA not applicable, SD standard deviation, TC total cholesterol





































































































































































































































Fig. 3 Changes from baseline in a HDL cholesterol, b LDL choles-
terol, c triglycerides, and d total cholesterol/HDL ratio at 48 weeks.
Boxes represent the first to third quartile; lines and symbols within the
box represent medians and means, respectively. Whiskers extend to
the most extreme observations within 1.5 times the length of the
interquartile range from the first and third quartiles. Points beyond the
whiskers are considered outliers. DRV/r darunavir/ritonavir, DTG
dolutegravir, EFV efavirenz, EFV/TDF/FTC efavirenz/tenofovir
disoproxil fumarate/emtricitabine, HDL high-density lipoprotein,
LDL low-density lipoprotein, RAL raltegravir
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In individuals receiving dolutegravir, levels of LDL-C, a
primary target of lipid-lowering therapies, minimally
increased to a mean concentration of 99 mg/dL at
48 weeks across the four clinical studies. This is just below
the 100 mg/dL target previously recommended by the
National Cholesterol Education Program (NCEP) guide-
lines for subjects with the highest risk of cardiovascular
disease [13]. On the other hand, increased levels of HDL-
C, which are associated with decreased risk of coronary
artery disease, rose from 43 mg/dL at baseline to 47 mg/dL
at 48 weeks. Furthermore, a mean change from baseline in
TC:HDL ratio of -0.1, which infers a low risk of cardio-
vascular disease, characterized the dolutegravir arms.
With respect to hypertriglyceridemia, which is consid-
ered an independent risk factor for cardiovascular disease,
individuals exposed to dolutegravir showed modest mean
increases in TG levels (from 114 to 122 mg/dL), which
were below the 200 mg/dL threshold used for recommen-
dation of therapy (‘borderline high’ according to 2001
NCEP guidelines) [14]. All of the above suggest a conve-
nient lipid profile of dolutegravir in ART-naive subjects
based on regimens including dolutegravir during 48 weeks
of combination therapy.
In the comparative analysis, similar lipid effects were
observed between the dolutegravir and raltegravir regi-
mens. Results from the SPRING-2 study showed minor
increases in TC, LDL-C, and TG levels in both arms
without reaching clinically significant concentrations at
48 weeks. The mean lipid changes observed in the ralte-
gravir arm were consistent with those previously reported
in the STARTMRK study, in which raltegravir had mini-
mal effects on lipid levels in ART-naive subjects [15].
Together, these results confirm the previous results
reported regarding the equivalent effect on lipids of the
INSTI drug class.
In the SINGLE study, there were larger mean increases
in TC, LDL-C, HDL-C, and TG in patients randomized to
efavirenz compared with those randomized to dolutegra-
vir. Similar effects on lipids were reported in efavirenz-
treated patients participating in several previous clinical
trials [16]. Of note, a larger increase of HDL-C in ef-
avirenz subjects probably balanced the mean TC:HDL
ratio between efavirenz and dolutegravir patients in the
current analysis.
In the FLAMINGO study, greater increases in TC, LDL-
C, and TG levels were observed in the ritonavir-boosted
darunavir arm. This is consistent with the effect of drugs in
the protease inhibitor (PI) class on serum lipids [17].
However, it should be noted that different antiretroviral
drugs within the same class may induce differential effects
on lipids. As an example, across a number of clinical
studies, atazanavir in combination with NRTIs has shown
consistently smaller increases in triglycerides and choles-
terol than combinations including lopinavir/ritonavir [18].
Nonetheless, it should be noted that a significant proportion
of the lipid effect of the PI-based regimens is related to the
concomitant use of the booster ritonavir with a PI. Note-
worthy, in contrast with elvitegravir and protease inhibi-
tors, the pharmacokinetic characteristics of dolutegravir
allow for its use without a pharmacological booster.
Standard measurements of cholesterol and triglycerides
may not fully reflect the complex changes in lipid metab-
olism induced by HIV and highly active ART. Other
markers of cardiovascular risk, including apolipoproteins,
d-dimer, and non-invasive imaging tools among others,
have been shown to provide additional information to
Table 5 Mean lipid changes from baseline to week 48 in the FLAMINGO study
Parameter Treatment Baseline Change from baseline Maximum post-baseline
emergent grade 3–4a
n Mean (SD) n Mean (SD) n/N (%)
TC (mg/dL) DTG 207 157.6 (33) 182 4.3 (24) 9/242 (4)
DRV/r 215 162.5 (35) 178 22.5 (33) 39/242 (16)
LDL-C (mg/dL) DTG 207 91.1 (29) 182 3.1 (20) 10/242 (4)
DRV/r 215 95.5 (29) 178 14.1 (25) 35/242 (14)
HDL-C (mg/dL) DTG 207 43.9 (13) 182 2.0 (9) NA
DRV/r 215 43.5 (13) 178 2.2 (10) NA
TC:HDL ratio DTG 222 3.9 (1) 197 0.0 (1) NA
DRV/r 227 4.1 (2) 188 0.4 (1) NA
Triglycerides (mg/dL) DTG 207 114.0 (66) 183 -5.5 (53) 2/242 (\1)
DRV/r 215 117.9 (67) 178 33.1 (73) 8/242 (3)
DAIDS Division of AIDS, DRV/r darunavir/ritonavir, DTG dolutegravir, HDL-C high-density lipoprotein cholesterol, LDL-C low-density
lipoprotein cholesterol, NA not applicable, SD standard deviation, TC total cholesterol
a DAIDS grading system
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predict a cardiovascular event. Nevertheless, traditional
risk factors such as increased cholesterol serum levels
remain significantly associated with a high risk of a car-
diovascular event and provide practical information for
clinical management of HIV-infected individuals [12].
The specific effect of background nucleosides on lipids
is not reported in this study. Nevertheless, it has been
reported that NRTIs, alone or co-formulated, could have
effects on lipid levels and could even have lipid-lowering
effects [19–22]. In this analysis, the distribution of the two
backbone options was balanced and comparable between
arms, ensuring an accurate interpretation of the lipid profile
of dolutegravir, except in the SINGLE study, where all
patients received dolutegravir with abacavir/lamivudine in
the dolutegravir arm versus the efavirenz arm, where all
patients received tenofovir/emtricitabine. We can then
hypothesize that the lipid-lowering effect of tenofovir
might counterbalance the lipid effect of efavirenz versus
the neutral lipid profile of dolutegravir.
Additional analysis of these and other studies, as well as
results from NRTI-sparing regimens, would provide addi-
tional information on the impact of NRTIs on lipid levels in
the context of combination therapy.
5 Conclusions
A broadly neutral lipid effect, as shown in this analysis,
adds to the strength of dolutegravir as an initial therapy for
the treatment of HIV. This is of particular importance for
an aging population with other risk factors for metabolic
syndrome and cardiovascular disease [23]. The data pre-
sented are limited to 48 weeks of exposure to antiretrovi-
rals within the context of clinical trials. An extended
follow-up and expanded use of dolutegravir in clinical
practice should help to further characterize its lipid profile.
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